Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 9/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 10/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649832 | 1.00 | OPRL1 (0.49) | OPRL1OPRM1OPRK1OPRD1CCR5 | |
| SCHEMBL649460 | 1.00 | OPRL1 (0.49) | OPRL1OPRM1OPRK1OPRD1CCR5 | |
| SCHEMBL649831 | 1.00 | OPRL1 (0.49) | OPRL1OPRM1OPRK1OPRD1CCR5 | |
| SCHEMBL649830 | 1.00 | OPRL1 (0.49) | OPRL1OPRM1OPRK1OPRD1CCR5 | |
| SCHEMBL10092903 | 0.88 | OPRL1 (0.47) | OPRL1OPRM1OPRK1OPRD1CCR5 | |
| SCHEMBL648172 | 0.88 | OPRL1 (0.47) | OPRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL3410004 | 0.87 | CCR5 (0.37) | OPRL1OPRM1OPRK1OPRD1CCR5 | |
| Azd-6088 SCHEMBL647335 | 0.86 | OPRL1 (0.46) | OPRL1OPRM1OPRK1OPRD1CCR5 | |
| Azd-6088 SCHEMBL649525 | 0.86 | OPRL1 (0.46) | OPRL1OPRM1OPRK1OPRD1CCR5 | |
| Azd-6088 SCHEMBL649526 | 0.86 | OPRL1 (0.46) | OPRL1OPRM1OPRK1OPRD1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | claimed |
| EP-2197843-B1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2011-12-28 | — | — | EP | claimed |
| EP-2197843-A1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | AstraZeneca AB (SE) | 2010-06-23 | — | — | EP | claimed |
| WO-2009034380-A1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | claimed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | claimed |
| US-20260147006-A1 | SCREENING METHOD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-28 | — | — | US | disclosed |
| US-12298319-B2 | Method for measuring alpha value of muscarinic M1 receptor positive allosteric modulators | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-05-13 | — | — | US | disclosed |
| US-20200182850-A1 | SCREENING METHOD | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-11 | — | — | US | disclosed |
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| US-8119661-B2 | Piperidine derivatives and their use as muscarinic receptor modulators | ASTRAZENECA AB (SE) | 2012-02-21 | — | — | US | disclosed |
| EP-2197843-B1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2011-12-28 | — | — | EP | disclosed |
| EP-2197843-B1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2011-12-28 | — | — | EP | disclosed |
| EP-2197843-A1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | AstraZeneca AB (SE) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009034380-A1 | PIPERIDINE DERIVATIVES AS AGONISTS OF MUSCARINIC RECEPTORS | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-20090076078-A1 | New compounds 966 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076078-A1 | New compounds 966 | OPRM1, OPRL1, OPRK1 | OPRL1 2/4885OPRM1 1/4885OPRK1 3/4885 |
| US-20200182850-A1 | SCREENING METHOD | CHRM1, CHRM2, CHRM4 | OPRL1 78/4885OPRM1 52/4885OPRK1 153/4885 |
| US-12298319-B2 | Method for measuring alpha value of muscarinic M1 receptor positive allosteric modulators | CHRM1, CHRM2, CHRM4 | OPRL1 99/4885OPRM1 40/4885OPRK1 146/4885 |
| US-20260147006-A1 | SCREENING METHOD | CHRM1, CHRM4, CHRM5 | OPRL1 84/4885OPRM1 56/4885OPRK1 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.